Novartis to acquire Tourmaline Bio for $1.4 billion – Reuters
- Novartis to acquire Tourmaline Bio for $1.4 billion Reuters
- Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Novartis
- TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders Business Wire
- Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range MarketWatch
- This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It. Barron’s